tetano
Editor, Senior Moderator
Medicine (Baltimore). 2020 Feb;99(7):e19095. doi: 10.1097/MD.0000000000019095. [h=1]Effectiveness, immunogenicity, and safety of influenza vaccines with MF59 adjuvant in healthy people of different age groups: A systematic review and meta-analysis.[/h]
Yang J[SUP]1,[/SUP][SUP]2[/SUP], Zhang J[SUP]1,[/SUP][SUP]2[/SUP], Han T[SUP]1,[/SUP][SUP]2[/SUP], Liu C[SUP]1,[/SUP][SUP]2[/SUP], Li X[SUP]1,[/SUP][SUP]2[/SUP], Yan L[SUP]1,[/SUP][SUP]2[/SUP], Yang B[SUP]1,[/SUP][SUP]2[/SUP], Yang X[SUP]1,[/SUP][SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Influenza is a severe disease burden among all age groups. This study aimed to review the efficacy of inactivated influenza vaccines with MF59 adjuvant and non-adjuvanted inactivated influenza vaccines among all age groups against specific influenza vaccine strains.
[h=4]METHODS:[/h] Literature search of PubMed, Embase, Medline, OVID, and Cochrane Library Trials (CENTRAL) was implemented up to March 1, 2019. Homogeneity qualified studies were included forData were extracted such as study country location, demographic characteristics, and measure outcomes, and were analyzed by a random effect model and sensitivity analyses to identify heterogeneity. Risk of bias was evaluated using the Cochrane Risk of Bias Tool.
[h=4]RESULTS:[/h] We retrieved 1,021 publications and selected 31 studies for full review, including 17 trials for meta-analysis and 6 trials for qualitative synthesis. MF59-adjuvanted influenza vaccines demonstrated better immunogenicity against specific vaccine virus strains compared to non-adjuvanted influenza vaccine both in healthy adult group (RR = 2.10; 95% CI: 1.28-3.44) and the healthy aged (RR = 1.26; 95% CI: 1.10-1.44).
[h=4]CONCLUSION:[/h] The quality of evidence is moderate to high for seroconversion and seroprotection rates of influenza vaccine. MF59-adjuvanted influenza vaccines are superior to non-adjuvanted influenza vaccines to enhance immune responses of vaccination in healthy adults and older adults, and could be considered for routine use especially the monovalent prepandemic influenza vaccines.
PMID: 32049815 DOI: 10.1097/MD.0000000000019095
Free full text
Yang J[SUP]1,[/SUP][SUP]2[/SUP], Zhang J[SUP]1,[/SUP][SUP]2[/SUP], Han T[SUP]1,[/SUP][SUP]2[/SUP], Liu C[SUP]1,[/SUP][SUP]2[/SUP], Li X[SUP]1,[/SUP][SUP]2[/SUP], Yan L[SUP]1,[/SUP][SUP]2[/SUP], Yang B[SUP]1,[/SUP][SUP]2[/SUP], Yang X[SUP]1,[/SUP][SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Influenza is a severe disease burden among all age groups. This study aimed to review the efficacy of inactivated influenza vaccines with MF59 adjuvant and non-adjuvanted inactivated influenza vaccines among all age groups against specific influenza vaccine strains.
[h=4]METHODS:[/h] Literature search of PubMed, Embase, Medline, OVID, and Cochrane Library Trials (CENTRAL) was implemented up to March 1, 2019. Homogeneity qualified studies were included forData were extracted such as study country location, demographic characteristics, and measure outcomes, and were analyzed by a random effect model and sensitivity analyses to identify heterogeneity. Risk of bias was evaluated using the Cochrane Risk of Bias Tool.
[h=4]RESULTS:[/h] We retrieved 1,021 publications and selected 31 studies for full review, including 17 trials for meta-analysis and 6 trials for qualitative synthesis. MF59-adjuvanted influenza vaccines demonstrated better immunogenicity against specific vaccine virus strains compared to non-adjuvanted influenza vaccine both in healthy adult group (RR = 2.10; 95% CI: 1.28-3.44) and the healthy aged (RR = 1.26; 95% CI: 1.10-1.44).
[h=4]CONCLUSION:[/h] The quality of evidence is moderate to high for seroconversion and seroprotection rates of influenza vaccine. MF59-adjuvanted influenza vaccines are superior to non-adjuvanted influenza vaccines to enhance immune responses of vaccination in healthy adults and older adults, and could be considered for routine use especially the monovalent prepandemic influenza vaccines.
PMID: 32049815 DOI: 10.1097/MD.0000000000019095
Free full text